Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia.

Conte, William L

Conte, William L.

Conte WL; Comprehensive MS Center, Methodist Hospitals, 200 E 89th Ave, Merrillville IN 46410, USA. Electronic address: billy.conte@gmail.com.

Mult Scler Relat Disord ; 44: 102315, 2020 09.

Article in English | MEDLINE | ID: covidwho-1386345

Subject(s)

Agammaglobulinemia/drug therapy; Antibodies, Monoclonal, Humanized/therapeutic use; COVID-19 Drug Treatment; COVID-19/virology; SARS-CoV-2/pathogenicity; Agammaglobulinemia/complications; Agammaglobulinemia/immunology; Antibodies, Viral/immunology; Antibody Formation/physiology; COVID-19/complications; Female; Humans; Middle Aged; SARS-CoV-2/drug effects

Keywords

COVID-19; Immunuglobulins; Multiple Sclerosis; Ocrelizumab; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Agammaglobulinemia / Antibodies, Monoclonal, Humanized / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Case report Topics: Long Covid Limits: Female / Humans / Middle aged Language: English Journal: Mult Scler Relat Disord Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google